CAJ | 학술논문

目的：探讨直肠癌患者癌组织XPG C46T基因多态性对新辅助放化疗疗效的影响。方法选取Ⅱ～Ⅲ期中低位直肠癌患者45例，手术治疗前均给予XELOX化疗（奥沙利铂联合卡培他滨）联合放疗，放疗结束6周行CT或MRI检查，评价疗效。采用RT-PCR法检测放化疗前XPG C46T基因型。结果放化疗有效27例、无效18例，有效率为60．00％。放化疗效果与直肠癌患者性别、年龄、病理类型、KPS评分均无关（ P均＞0．05）。有效患者直肠癌组织XPG C46T基因型C／C为18例、无效者为3例（P＜0．05），C／T分别为6、9例（P＜0．05），T／T分别为3、6例（ P＜0．05）。结论新辅助放化疗有效者XPG C46T基因C／C基因型比例高于无效者，C／T及T／T基因型比例低于无效者；检测XPG C46 T基因多态性可用于预测Ⅱ～Ⅲ期直肠癌新辅助放化疗疗效。
목적：탐토직장암환자암조직XPG C46T기인다태성대신보조방화료료효적영향。방법선취Ⅱ～Ⅲ기중저위직장암환자45례，수술치료전균급여XELOX화료（오사리박연합잡배타빈）연합방료，방료결속6주행CT혹MRI검사，평개료효。채용RT-PCR법검측방화료전XPG C46T기인형。결과방화료유효27례、무효18례，유효솔위60．00％。방화료효과여직장암환자성별、년령、병리류형、KPS평분균무관（ P균＞0．05）。유효환자직장암조직XPG C46T기인형C／C위18례、무효자위3례（P＜0．05），C／T분별위6、9례（P＜0．05），T／T분별위3、6례（ P＜0．05）。결론신보조방화료유효자XPG C46T기인C／C기인형비례고우무효자，C／T급T／T기인형비례저우무효자；검측XPG C46 T기인다태성가용우예측Ⅱ～Ⅲ기직장암신보조방화료료효。
Objective To investigate the effect of XPG C46T gene polymorphisms in rectal cancer tissues on neoadju-vant chemoradiotherapy .Methods Forty-five patients with low rectal cancer (Ⅱ-Ⅲmidterm) were given XELOX chemo-therapy ( oxaliplatin combined with capecitabine ) before surgery .CT or MRI examination was conducted to evaluate the ef-ficacy after radiotherapy 6-8 weeks.The XPG C46T genotype was detected before and after radiotherapy by RT-PCR.Re-sults After neoadjuvant chemoradiotherapy , 27 cases were effective , 18 cases were non-effective, and the effective rate was 60.00%.The efficacy of neoadjuvant chemoradiation was not related with gender , age, pathological type and KPS score of colorectal cancer patients (all P>0.05).There were 18 cases of XPG C46T genotype C/C in the rectal cancer tis-sues of patients with effective neoadjuvant chemoradiotherapy , 3 cases in patients with non-effective neoadjuvant chemora-diotherapy (P<0.05);there were respectively 6 cases of C/T and 9 cases in patients with effective and in patients with non-effective neoadjuvant chemoradiotherapy (P<0.05);T/T were respectively 3 cases and 6 cases in patients with effec-tive and in patients with non-effective neoadjuvant chemoradiotherapy (P<0.05).Conclusions The XPG C46T gene C/C genotype ratio in patients with effective neoadjuvant chemoradiotherapy is higher , C/T and T/T genotype ratios are lower than those of the invalid ones .The detection of XPG C46T gene polymorphism can be used to predict the curative effect of colorectal cancer in Ⅱ-Ⅲstage.